NCT/Study#

NCT03589326 /

PONATINIB-3001

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With ACTIVEly Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With ACTIVEly Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

DISEASE GROUP:
Leukemia
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: